Maze Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
MAZE$34.91+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $294,374 | $196,812 |
| Prepaid expenses and other current assets | 5,333 | 4,859 |
| Total current assets | 299,707 | 201,671 |
| Property and equipment, net | 6,314 | 6,668 |
| Restricted cash | 1,089 | 1,088 |
| Operating lease right-of-use asset | 22,483 | 23,250 |
| Other assets | 3,247 | 7,865 |
| Total assets | $332,840 | $240,542 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $2,404 | $1,939 |
| Accrued expenses and other current liabilities | 11,539 | 14,102 |
| Operating lease liabilities, current | 4,674 | 4,632 |
| Total current liabilities | 18,617 | 20,673 |
| Operating lease liabilities, net of current portion | 21,149 | 21,996 |
| Other liabilities, non-current | 1,006 | 969 |
| Total liabilities | 40,772 | 43,638 |
| Commitments and contingencies (Note 8) | ||
| Redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding as of March 31, 2025; 298,205,027 shares authorized and 297,205,041 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $502,390 as of December 31, 2024 | — | 508,087 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value; 10,000,000 and no shares authorized as of March 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of March 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 500,000,000 and 410,000,000 shares authorized as of March 31, 2025 and December 31, 2024, respectively; 43,797,166 and 2,446,864 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively; 10,372 shares subject to repurchase as of March 31, 2025 and December 31, 2024 | 44 | 2 |
| Additional paid-in-capital | 683,237 | 47,242 |
| Accumulated deficit | (391,213) | (358,427) |
| Total stockholders’ equity (deficit) | 292,068 | (311,183) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $332,840 | $240,542 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.